Você está deixando o Portal Médico GSK

Você está prestes a deixar o site da GSK. Ao clicar neste link, você será direcionado a um site que não pertence ou é controlado pela GSK. Portanto, a GSK não é responsável por demais conteúdos presentes neste site.

Continuar

Voltar

Você mais próximo do European Respiratory Society Meeting. Confira os principais destaques do quarto dia do evento. 

Video player requires JavaScript enabled. You can download this video here: https://edgesuite.gskstatic.com/HealthSites/Health/Brazil/MP4/20170914_Respiratorio_ERS_Jose_Jardim.mp4

O que mudou no GOLD 2017? As principais alterações na estratégia de tratamento da DPOC com o Dr. José Jardim (CRM-SP 17819), Professor da Universidade Federal de São Paulo e palestrante voluntário.

Video player requires JavaScript enabled. You can download this video here: https://edgesuite.gskstatic.com/HealthSites/Health/Brazil/MP4/20170914_Respiratorio_ERS_Emilio_Pizzichini.mp4

Asma retorna ao destaque das apresentações do ERS 2017. Novidades sobre o controle da asma abordadas no congresso com o Dr. Emilio Pizzichini (CRM-SC 3063), Professor da Universidade Federal de Santa Catarina e Especialista Global GSK.

Video player requires JavaScript enabled. You can download this video here: https://edgesuite.gskstatic.com/HealthSites/Health/Brazil/MP4/20170914_Respiratorio_ERS_Ronald_Dahl.mp4

Hiperinsuflação, implicações terapêuticas e a importância da identificação de fenótipos na DPOC com o Professor Ronald Dahl, Especialista Global GSK.

Video player requires JavaScript enabled. You can download this video here: https://edgesuite.gskstatic.com/HealthSites/Health/Brazil/MP4/20170914_Respiratorio_ERS_Carlos_Jardim.mp4

Diferentes mecanismos de desenvolvimento da HAP com o Dr. Carlos Jardim (CRM-SP 97360), Médico da disciplina de Pneumologia do Icor/USP e Especialista Global GSK.

Video player requires JavaScript enabled. You can download this video here: https://edgesuite.gskstatic.com/HealthSites/Health/Brazil/MP4/20170913_Respiratorio_ERS_Paulo_Voluntario.mp4

Como a reabilitação pulmonar em pacientes com DPOC e fenótipo exacerbador pode impactar na qualidade de vida, com Dr. Paulo Zimermann (CRM-RS 16458), professor da Universidade Federal Ciências da Saúde de Porto Alegre e palestrante voluntário.

 

Confira os destaques do 3º dia do evento 

Confira os destaques do 2º dia do evento

Confira os destaques do 1º dia do evento

  • Referências

    Entrevista Dr. Emilio Pizzichini

    1.     WENZEL, SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nature Med, 18(5): 716-25, 2012.

    2.     KATZ, LE. et al. Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma. Ann Am Thorac Soc, 11(4): 531-6, 2014.

    3.     NEJMAN-GRYZ, P. et al. Epithelial derived cytokines IL-25, IL-33 and TSLP in obstructive lung diseases. In: ERS, 2017, Milão. PA571. Disponível em: < http://k4.ersnet.org/prod/v2/front/program/?e=42>. Acesso em: 14 set. 2017.

     

    BR/RESP/0129/17b – Setembro/2017

     

    Entrevista Dr. Carlos Jardim

    1.     RAINA, A.; HUMBERT, M. Risk assessment in pulmonary arterial hypertension. European Respiratory Review, 25: 390-398, 2016.

    2.     SIMONNEAU, G. et al. Future perspectives in pulmonary arterial hypertension. European Respiratory Review, 25: 381-389, 2016.

    3.     GRAARUP, J. et al. Patient engagement and self-management in pulmonary arterial hypertension. European Respiratory Review, 25: 399-407, 2016

    4.      ARMSTRONG, I. et al. PHA-UK living with Pulmonary Hypertension 2016 Survey. In: ERS, 2017, Milão. PA2419. Disponível em: <http://k4.ersnet.org/prod/v2/front/program/?e=42>. Acesso em: 14 set. 2017.

     

    BR/RESP/0129/17c – Setembro/2017

     

    Entrevista Dr. José Jardim

    5.     VESTBO, J.  et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). European Respiratory Journal, 31: 869-87, 2008.

    6.     MILLER, BE. et al. Plasma Fibrinogen Qualification as a Drug Development Tool in Chronic Obstructive Pulmonary Disease. Perspective of the Chronic Obstructive Pulmonary Disease Biomarker Qualification Consortium. Am J Respir Crit Care Med, 193(6): 607-13, 2016.

    7.     LOMAS, DA. et al. Evaluation of serum CC-16 as a biomarker for COPD in the ECLIPSE cohort. Thorax, 63 1032-1034, 2008. 

    8.     CHRISTENSON, SA. et al. Asthma-COPD overlap. Clinical relevance of genomic signatures of type 2 inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 191(7): 758–66, 2015.

    9.     OBEIDAT, M. et al. Molecular mechanisms underlying variations in lung function: a systems genetics analysis. Lancet Respir Med, 3: 782–95, 2015.

    10.  GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE. Global strategy for the Diagnosis, Management and Prevention of COPD. Updated 2017. Disponível em: <http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/>.  Acesso em: 14 set. 2017.

    11.  DONALDSON, GC. et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax, 57: 847-852, 2002.

    12.  DONALDSON, GC. et al. Airway and Systemic Inflammation and Decline in Lung Function in Patients With COPD. Chest, 128: 1995–2004, 2005.

     

    BR/RESP/0129/17e – Setembro/2017

     

    Entrevista Dr. Ronald Dahl

    1.     POBEREZHETS, V. et al. Clinical features and quality of life in patients with different metabolic phenotypes of COPD. In: ERS, 2017, Milão. PA3673. Disponível em: <http://k4.ersnet.org/prod/v2/front/program/?e=42>. Acesso em: 14 set. 2017.

    2.     HOHFELD, JM. et al. Late Breaking Abstract – Lung deflation with Indacaterol-Glycopyrronium improves cardiac function in COPD patients: The CLAIM Study. In: ERS, 2017, Milão. OA2899. Disponível em: <http://k4.ersnet.org/prod/v2/front/program/?e=42>. Acesso em: 14 set. 2017.

    3.     RUBIO, CM. et al. Identification and distribution of COPD phenotypes in clinical practice according to Spanish COPD Guidelines: the FENEPOC study. Int J Chron Obstruct Pulmon Dis, 12: 2373-83, 2017.

    4.     LOUREIRO, CC. et al. Blurred lines. Eosinophilic COPD: ACOS or COPD phenotype? Rev Port Pneumol, 22(5): 279-82, 2016.

     

    BR/RESP/0129/17f – Setembro/2017

     

    Entrevista Dr. Paulo Zimermann

    1.     BOHN JR., I. et al. Pulmonary Rehabilitation in COPD Phenotype Exacerbator. In: ERS, 2017, Milão/Itália. Thematic Poster: Pulmonar Rehabilitation in Patients with Chronic Lung Diseases. PA758. Disponível em: <http://ers-eposter.key4events.com/42/52480.pdf>. Acesso em: 14 set. 2017.